Similar articles

• Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.

  Clark PE. Clark PE. Eur Urol. 2009 Jun;55(6):1343-4. doi: 10.1016/j.eururo.2009.01.045. Epub 2009 Jan 30. Eur Urol. 2009. PMID: 19201523 No abstract available.
• Vaccine therapy in patients with renal cell carcinoma.

  Van Poppel H, Joniau S, Van Gool SW. Van Poppel H, et al. Eur Urol. 2009 Jun;55(6):1333-42. doi: 10.1016/j.eururo.2009.01.043. Epub 2009 Jan 30. Eur Urol. 2009. PMID: 19201522 Review.
• Active and passive immunotherapy: vaccines and antibodies.

  Oosterwijk E, Divgi C, Bander NH. Oosterwijk E, et al. BJU Int. 2007 May;99(5 Pt B):1301-4. doi: 10.1111/j.1464-410X.2007.06835.x. BJU Int. 2007. PMID: 17441928 Review. No abstract available.
• High-dose interleukin-2 in metastatic renal cell carcinoma.

  Fernández-Rodríguez R, de Argumedo GL, Mañé JM, Muñoz A, Ferreiro J, Fuente N, López-Vivanco G. Fernández-Rodríguez R, et al. J Clin Oncol. 2005 Sep 20;23(27):6797-8; author reply 6798-9. doi: 10.1200/JCO.2005.02.1709. J Clin Oncol. 2005. PMID: 16170190 No abstract available.
• Immunotherapy and prognostic factors.

  Fumagalli LA, Brivio F. Fumagalli LA, et al. J Clin Oncol. 2006 Sep 1;24(25):4218-9; author reply 4219-20. doi: 10.1200/JCO.2006.07.4211. J Clin Oncol. 2006. PMID: 16943541 No abstract available.